share_log

8-K: Cassava Sciences Resolves SEC Investigation

8-K: Cassava Sciences Resolves SEC Investigation

8-K:Cassava Sciences解决了SEC 调查
美股SEC公告 ·  09/27 07:39

Moomoo AI 已提取核心信息

On September 26, 2024, Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, announced a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the investigation into the company's disclosures about its Phase 2b clinical trial of simufilam for Alzheimer's treatment. The SEC had alleged that Cassava's disclosures contained materially misleading statements and omissions. Without admitting or denying the allegations, Cassava agreed to a permanent injunction against future violations and will pay a $40 million civil penalty. This settlement is pending final approval by a U.S. District Court. Cassava had previously reserved this amount for the potential settlement. Additionally, two former senior employees of Cassava settled with the SEC on related negligence-based disclosure charges. The...Show More
On September 26, 2024, Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, announced a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the investigation into the company's disclosures about its Phase 2b clinical trial of simufilam for Alzheimer's treatment. The SEC had alleged that Cassava's disclosures contained materially misleading statements and omissions. Without admitting or denying the allegations, Cassava agreed to a permanent injunction against future violations and will pay a $40 million civil penalty. This settlement is pending final approval by a U.S. District Court. Cassava had previously reserved this amount for the potential settlement. Additionally, two former senior employees of Cassava settled with the SEC on related negligence-based disclosure charges. The company has also implemented remedial measures to enhance corporate governance. Cassava's CEO, Richard Barry, expressed relief at resolving the matter, allowing the company to focus on ongoing Phase 3 trials of simufilam. Cassava anticipates an operational cash use of $80 to $90 million for the second half of 2024, inclusive of the penalty, and estimates year-end cash balances to be between $117 to $127 million.
2024年9月26日,Cassava Sciences公司,一家专注于阿尔茨海默病的生物技术公司,宣布与美国证券交易委员会(SEC)达成和解,涉及公司关于其阿尔茨海默病治疗simufilam的第20期临床试验的披露进行的调查。SEC声称Cassava的披露包含实质性误导性陈述和遗漏。在不承认或否认指控的情况下,Cassava同意永久禁令以防止未来违规行为,并支付4000万美元的民事罚款。该和解尚待美国地方法院最终批准。Cassava此前已为潜在和解预留了这笔金额。此外,Cassava的两名前高级雇员就相关失职披露指控与SEC达成了和解。公司还采取了补救措施以加强公司治理。Cassava的首席执行官Richard Barry对解决此事表示如释重负,使该公司能够专注于simufilam的正在进行中的第3期试验。Cassava预计2024年下半年的运营现金支出为8000万至9亿元,包括罚款,并估计年底现金余额在1.17亿至1.27亿之间。
2024年9月26日,Cassava Sciences公司,一家专注于阿尔茨海默病的生物技术公司,宣布与美国证券交易委员会(SEC)达成和解,涉及公司关于其阿尔茨海默病治疗simufilam的第20期临床试验的披露进行的调查。SEC声称Cassava的披露包含实质性误导性陈述和遗漏。在不承认或否认指控的情况下,Cassava同意永久禁令以防止未来违规行为,并支付4000万美元的民事罚款。该和解尚待美国地方法院最终批准。Cassava此前已为潜在和解预留了这笔金额。此外,Cassava的两名前高级雇员就相关失职披露指控与SEC达成了和解。公司还采取了补救措施以加强公司治理。Cassava的首席执行官Richard Barry对解决此事表示如释重负,使该公司能够专注于simufilam的正在进行中的第3期试验。Cassava预计2024年下半年的运营现金支出为8000万至9亿元,包括罚款,并估计年底现金余额在1.17亿至1.27亿之间。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息